Mustapha Si-Tahar
  • E-mail :[email]
  • Phone : +33 2 47 36 60 45
  • Location : Tours, France
Last update 2015-05-12 19:45:06.568

Mustapha Si-Tahar U1100 Laboratory Head and Team leader - Study Center of Respiratory Pathologies

Course and current status

Head of the Study Center of Respiratory Pathologies ("CEPR") and leader of the team "Respiratory infection & Immunity"


  • 1997, Ph.D in Vascular Inflammation, Pasteur Institute , Paris, France

Post-doctoral training

  • 3/2000 – 12/2000: Postdoctoral Research Fellow, Massachusetts General Hospital, Harvard Medical School, Infectious Disease Unit, Charlestown, MA, 02129, USA
  • 8/1997 -2/2000: Postdoctoral Research Fellow, Emory University School of Medicine, Epithelial Pathobiology Unit, Atlanta, GA, 30322, USA

Present Status

  • Director of Research (DR2) at INSERM

Centre d'Etude des Pathologies Respiratoires (CEPR)
Faculté de Médecine, Université F. Rabelais
10, boulevard Tonnellé
37032 Tours cedex, France 

e-mail :; Tel :  (+33)  2 47 36 60 45

Previous position

  • 1/2001 – 08/2011: Group leader, Research Unit "Innate defense and inflammation", Institut Pasteur, Inserm U874, Paris, France

Research keywords

  • Mechanisms of lung infection (mostly by Pseudomonas aeruginosa and influenza virus)
  • Innate immunity
  • Cell signaling
  • Epithelial cell biology

Scientific summary

My research team (entitled "Respiratory infection and immunity") develops translational research programs in the field of respiratory infections.
The strengths of this team are based on the members who are associated with it. This includes scientific experts in immunology and microbiology as well as clinicians.
The team develops programs using molecular and mechanistic approaches, in vivo experiments as well as pre-clinical and clinical investigation.

Currently, our main research activities include:

  •  the study of inflammatory and antimicrobial signaling in the lung mucosa (including the IL-22 receptor and TRPV4-dependent pathways);
  • the study of virulence factors associated with the opportunistic bacteria Pseudomonas aeruginosa;
  • the study of innovative antimicrobial molecules (such as the cationic polypeptide PLK);
  • the study of early markers of P. aeruginosa infection in mechanically-ventilated patients.
Image d’exemple